News of the WeekGene Therapy

FDA Moves Against Penn Scientist

Science  15 Dec 2000:
Vol. 290, Issue 5499, pp. 2049-2051
DOI: 10.1126/science.290.5499.2049b

You are currently viewing the summary.

View Full Text

Via your Institution

Log in through your institution

Log in through your institution


Summary

The U.S. Food and Drug Administration (FDA) has begun proceedings that could disqualify gene therapy researcher James Wilson of the University of Pennsylvania in Philadelphia from conducting any future clinical trials. Wilson, who is head of the university's Institute for Human Gene Therapy, oversaw the trial in which 18-year-old Jesse Gelsinger died after a genetically altered virus was injected into his liver. Disqualification is the harshest penalty the FDA can impose on an investigator.

Related Content